TearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.
Visionary Ventures
Life sciences venture capital fund investing in ophthalmology and medical aesthetics.
